---
status: "📝 Draft"
category: "dashboard"
type: "checklist"
due: "2026-04-01"
priority: "P0-Critical"
tags: [review, red-team, quality-assurance]
created: "2026-03-22"
updated: "2026-03-22"
---
# 🔴 RED TEAM REVIEW CHECKLIST

> Systematic adversarial review of the ARPA-H Delphi Solution Summary before submission.

## Scientific Rigor

- [ ] Are all 4 quantum protection architectures supported by peer-reviewed evidence?
- [ ] Is the QPI model mathematically defined with clear assumptions?
- [ ] Are cancer↑ / aging↓ signatures literature-backed for each candidate?
- [ ] Are effect sizes reported where available?
- [ ] Any logical gaps in the cancer-amplification / aging-decoherence framework?
- [ ] Are alternative explanations addressed?

## Technical Feasibility

- [ ] Is Probius QES sensitivity sufficient for the claimed metabolite detection?
- [ ] Sample volume (2–4 µL) adequate for all spectral targets?
- [ ] Are spectral targets (NADH 340/460, FAD 450/525, GSH thiol, ATP phosphate) validated?
- [ ] Is the swarm AI pipeline reproducible and auditable?
- [ ] Are QPI weight training assumptions realistic for available sample sizes?

## Clinical Translation

- [ ] IRB pathway clear for both UCB and UCSF?
- [ ] Sample collection feasible at proposed scale (n=50 → n=200)?
- [ ] Clinical endpoints defined and measurable?
- [ ] Regulatory strategy identified (510(k) vs De Novo)?
- [ ] Patient consent and HIPAA compliance addressed?

## Budget & Timeline

- [ ] Budget realistic for proposed scope?
- [ ] Milestones achievable within stated timelines?
- [ ] Contingency plans for key risks?
- [ ] Personnel justified across 3 institutions?
- [ ] Equipment costs accounted for (QES cartridges, spectroscopy time)?

## Narrative Coherence

- [ ] Does the executive summary compel within 1 page?
- [ ] Is the cancer-aging connection clear to non-specialists?
- [ ] Are figures/tables effective and self-explanatory?
- [ ] Is the 6-page limit respected with appropriate density?
- [ ] Does the narrative flow logically from problem → insight → solution → impact?

## Competitive Landscape

- [ ] How does this differ from existing metabolomics approaches (mass spec, NMR)?
- [ ] What is the technical/IP moat (QPI model, Probius QES, swarm AI)?
- [ ] Are competitors acknowledged and differentiated against?
- [ ] Is the quantum biology framing an asset or liability for reviewers?

## Known Weaknesses

| # | Weakness | Mitigation | Status |
|---|---|---|---|
| 1 | Small initial sample sizes (n=50, n=30) | Phased expansion design; power analysis for minimum detectable effects | Open |
| 2 | QPI model unvalidated in clinical setting | Benchmark against Lanzara ground truth; pre-register validation criteria | Open |
| 3 | Regulatory pathway uncertain for novel biomarker composite | Early FDA pre-submission meeting; 510(k) predicate search | Open |
| 4 | Swarm AI reproducibility concerns | Version-locked agent profiles; artifact validation checklist; human review gate | Open |
| 5 | Team coordination across 3 institutions (UCB, MIT, UCSF) | Biweekly cross-site meetings; shared vault; dedicated project manager | Open |

## Review Log

| Date | Reviewer | Section | Finding | Resolution | Status |
|---|---|---|---|---|---|
| — | — | — | — | — | — |

## Links

- [[03-Grants/ARPA-H-Delphi-Solution-Summary]]
- [[00-Flight-Deck/Aviation-Checklist]]
- [[01-Core-Thesis/Core-Thesis]]
